Earnings dates and session timing shown here are aggregated from third-party sources, are frequently estimated, and are subject to change or confirmation by the reporting company. Nothing on this site is financial advice.
Talphera Inc. is a pioneering biotechnology company dedicated to advancing peptide-based therapies for rare diseases and significant unmet medical needs. Its promising pipeline, especially in developing innovative cancer treatments, highlights the firm's potential for substantial growth within the biopharmaceutical industry. Committed to rigorous research and focused on delivering transformative health solutions, Talphera represents a compelling investment opportunity for institutional investors seeking to capitalize on the dynamic biotech landscape.
Quotes and fundamental data are delayed and provided for informational purposes only — nothing on this page is financial advice. Figures are as reported by the company and its data providers and may be revised. Estimates reflect analyst consensus at the time of each report.
$1.19
| Quarter | EPS | Revenue | Price move | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Est | Adj | Result | GAAP | Est | Actual | Surprise | 1D Pre | On-Day | 1D Post | |
Q ended Jun 30, 2026 Reported Aug 12, 2026 | $-0.07 | $-0.06 | Beat +14.3% | $-0.06 | $0 | $0 | — | 1D Pre+4.3% | On-Day-4.8% | 1D Post-13.6% |
Q ended Mar 31, 2026 Reported May 13, 2026 | $-0.08 | $-0.05 | Beat +37.5% | $-0.04 | $0 | $0 | — | 1D Pre-1.2% | On-Day+5.1% | 1D Post-0.4% |
Q ended Dec 31, 2025 Reported Mar 23, 2026 | $-0.07 | $-0.06 | Beat +14.3% | |||||||
Dashed outlines show the analyst consensus estimate for periods where one was published. Hover or tap a bar for exact figures. Values as reported; not adjusted for splits after the report date.
| — |
| $0 |
| $0 |
| — |
| 1D Pre+3.0% |
| On-Day-3.8% |
| 1D Post-8.9% |
Q ended Sep 30, 2025 Reported Nov 12, 2025 | $-0.11 | $-0.11 | Met 0.0% | — | $0 | $1.0K | — | 1D Pre+1.6% | On-Day0.0% | 1D Post-18.6% |